Exelixis Inc Increase (Decrease) in Accounts and Other Receivables
Exelixis Inc (EXEL) reported Increase (Decrease) in Accounts and Other Receivables of $15.64 million for the 9-month period ending 2018-09-28, per its 10-Q filed 2018-11-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2018-11-01
- Exelixis Inc increase (decrease) in accounts and other receivables for the quarter ending 2018-09-28 was -$70.32M, a 250.72% decline year-over-year.
- Exelixis Inc increase (decrease) in accounts and other receivables for the quarter ending 2018-06-29 was $75.21M, a 724.53% increase year-over-year.
- Exelixis Inc increase (decrease) in accounts and other receivables for the quarter ending 2018-03-30 was $10.76M.
- Exelixis Inc increase (decrease) in accounts and other receivables for the quarter ending 2017-12-29 was -$8.40M.
- Exelixis Inc increase (decrease) in accounts and other receivables for fiscal 2017 was $40.84M, a 10.37% increase from fiscal 2016.
- Exelixis Inc increase (decrease) in accounts and other receivables for fiscal 2016 was $37.00M.
- Exelixis Inc increase (decrease) in accounts and other receivables for fiscal 2016 was $35.32M, a 6440.37% increase from fiscal 2016.
- Exelixis Inc increase (decrease) in accounts and other receivables for fiscal 2016 was $540.00K.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 3 month as first filed | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 6 month as first filed | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 9 month as first filed | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|---|---|---|
| 2018-09-28 | -$70.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $4.89M derived: sum of 2 quarters · filed 2018-11-01 | $15.64M 10-Q · filed 2018-11-01 | $7.24M derived: sum of 4 quarters · filed 2018-11-01 | |||
| 2018-06-29 | $75.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $85.97M 10-Q · filed 2018-08-01 | $77.57M derived: sum of 3 quarters · filed 2018-08-01 | $124.23M derived: sum of 4 quarters · filed 2018-08-01 | |||
| 2018-03-30 | $10.76M 10-Q · filed 2018-05-02 | $2.35M derived: sum of 2 quarters · filed 2018-05-02 | $49.01M derived: sum of 3 quarters · filed 2018-05-02 | ||||
| 2017-12-29 | -$8.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $38.26M derived: sum of 2 quarters · filed 2018-02-26 | $40.84M 10-K · filed 2018-02-26 | ||||
| 2017-09-30 | $46.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $49.24M 10-Q · filed 2017-11-01 | |||||
| 2017-09-29 | $46.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $55.78M derived: sum of 2 quarters · filed 2018-11-01 | $49.24M 10-Q · filed 2018-11-01 | $1.22M derived: sum of 4 quarters · filed 2018-11-01 | |||
| 2017-06-30 | $9.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $2.58M 10-Q · filed 2017-08-02 | -$45.44M derived: sum of 3 quarters · filed 2018-05-02 | $28.03M derived: sum of 4 quarters · filed 2018-05-02 | |||
| 2017-03-31 | -$6.54M 10-Q · filed 2017-05-01 | -$54.56M derived: sum of 2 quarters · filed 2018-05-02 | $18.91M derived: sum of 3 quarters · filed 2018-05-02 | $25.50M derived: sum of 4 quarters · filed 2018-05-02 | |||
| 2016-12-31 | -$48.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $25.45M derived: sum of 2 quarters · filed 2017-11-01 | $32.05M derived: sum of 3 quarters · filed 2017-11-01 | $37.00M 10-K · filed 2017-02-27 | |||
| 2016-12-30 | $35.32M 10-K · filed 2018-02-26 | ||||||
| 2016-09-30 | $73.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $80.07M derived: sum of 2 quarters · filed 2017-11-01 | $85.03M 10-Q · filed 2017-11-01 | $85.92M 10-Q · filed 2016-11-03 | $86.71M derived: sum of 4 quarters · filed 2017-11-01 | ||
| 2016-06-30 | $6.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $11.55M 10-Q · filed 2017-08-02 | $12.36M 10-Q · filed 2016-08-03 | $13.23M derived: sum of 3 quarters · filed 2017-08-02 | $12.94M derived: sum of 4 quarters · filed 2017-08-02 | ||
| 2016-03-31 | $4.96M 10-Q · filed 2017-05-01 | $4.94M 10-Q · filed 2016-05-04 | $6.64M derived: sum of 2 quarters · filed 2017-05-01 | $6.35M derived: sum of 3 quarters · filed 2017-05-01 | $6.89M derived: sum of 4 quarters · filed 2017-05-01 | ||
| 2016-01-01 | $540.00K 10-K · filed 2018-02-26 | ||||||
| 2015-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $1.39M derived: sum of 2 quarters · filed 2017-02-27 | $1.94M derived: sum of 3 quarters · filed 2017-02-27 | $646.00K 10-K · filed 2017-02-27 | |||
| 2015-09-30 | -$288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $258.00K derived: sum of 2 quarters · filed 2016-11-03 | -$1.03M 10-Q · filed 2016-11-03 | -$874.00K derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-06-30 | $546.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$746.00K 10-Q · filed 2016-08-03 | -$586.00K derived: sum of 3 quarters · filed 2017-02-27 | -$898.00K derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-03-31 | -$1.29M 10-Q · filed 2016-05-04 | -$1.13M derived: sum of 2 quarters · filed 2017-02-27 | -$1.44M derived: sum of 3 quarters · filed 2017-02-27 | -$867.00K derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$152.00K derived: sum of 2 quarters · filed 2017-02-27 | $425.00K derived: sum of 3 quarters · filed 2017-02-27 | $941.00K 10-K · filed 2017-02-27 | |||
| 2014-09-30 | -$312.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $265.00K derived: sum of 2 quarters · filed 2015-11-10 | $781.00K 10-Q · filed 2015-11-10 | -$449.00K derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $1.09M 10-Q · filed 2015-08-11 | -$137.00K derived: sum of 3 quarters · filed 2016-02-29 | $825.00K derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $516.00K 10-Q · filed 2015-04-30 | -$714.00K derived: sum of 2 quarters · filed 2016-02-29 | $248.00K derived: sum of 3 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$268.00K derived: sum of 2 quarters · filed 2016-02-29 | $1.19M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $962.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $2.42M 10-Q · filed 2014-11-04 | |||||
| 2013-06-30 | $1.46M 10-Q · filed 2014-07-31 | ||||||
| 2012-12-31 | -$27.04M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |